Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Charles River Labs (CRL) PT Raised to $301 at Credit Suisse
February 17, 2021 4:13 PM ESTCredit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.
The analyst comments "CRLs 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It... More
Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus
February 17, 2021 7:11 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.29 better than the analyst estimate of $2.10. Revenue for the quarter came in at $791 million versus the consensus estimate of $756.86 million.
Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 Announces Definitive Agreement to Acquire Cognate BioServices, A Premier, Cell and Gene Therapy CDMOGUIDANCE:
Charles River Laboratories sees FY2021 EPS of... More
